Kabiven In Plastic Container is a drug owned by Fresenius Kabi Usa Llc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 03, 2036. Details of Kabiven In Plastic Container's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12390398 | Connector For A Medical Container |
May, 2036
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Kabiven In Plastic Container's patents.
Latest Legal Activities on Kabiven In Plastic Container's Patents
Given below is the list of recent legal activities going on the following patents of Kabiven In Plastic Container.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 26 Aug, 2025 | US12390398 |
| Email Notification | 19 Aug, 2025 | US12390398 |
| Patent Issue Date Used in PTA Calculation | 19 Aug, 2025 | US12390398 |
| Patent eGrant Notification | 19 Aug, 2025 | US12390398 |
| Mail Patent eGrant Notification | 19 Aug, 2025 | US12390398 |
| Recordation of Patent eGrant | 19 Aug, 2025 | US12390398 |
| Email Notification | 07 Aug, 2025 | US12390398 |
| Issue Notification Mailed | 06 Aug, 2025 | US12390398 |
| Dispatch to FDC | 23 Jul, 2025 | US12390398 |
| Application Is Considered Ready for Issue | 23 Jul, 2025 | US12390398 |
US patents provide insights into the exclusivity only within the United States, but
Kabiven In Plastic Container is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Kabiven In Plastic Container's family patents as well as insights into
ongoing legal events
on those patents.
Kabiven In Plastic Container's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Kabiven In Plastic Container's generic launch date based on the expiry of its last outstanding patent is estimated to be May 03, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Kabiven In Plastic Container Generics:
There are no approved generic versions for Kabiven In Plastic Container as of now.
Alternative Brands for Kabiven In Plastic Container
There are several other brand drugs using the same active ingredient (Amino Acids; Calcium Chloride; Dextrose; Magnesium Sulfate; Potassium Chloride; Sodium Acetate; Sodium Glycerophosphate; Soybean Oil) as Kabiven In Plastic Container. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Fresenius Kabi Usa |
|
About Kabiven In Plastic Container
Kabiven In Plastic Container is a drug owned by Fresenius Kabi Usa Llc. Kabiven In Plastic Container uses Amino Acids; Calcium Chloride; Dextrose; Magnesium Sulfate; Potassium Chloride; Sodium Acetate; Sodium Glycerophosphate; Soybean Oil as an active ingredient. Kabiven In Plastic Container was launched by Fresenius Kabi in 2014.
Approval Date:
Kabiven In Plastic Container was approved by FDA for market use on 25 August, 2014.
Active Ingredient:
Kabiven In Plastic Container uses Amino Acids; Calcium Chloride; Dextrose; Magnesium Sulfate; Potassium Chloride; Sodium Acetate; Sodium Glycerophosphate; Soybean Oil as the active ingredient. Check out other Drugs and Companies using Amino Acids; Calcium Chloride; Dextrose; Magnesium Sulfate; Potassium Chloride; Sodium Acetate; Sodium Glycerophosphate; Soybean Oil ingredient
Dosage:
Kabiven In Plastic Container is available in emulsion form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML) | EMULSION | Prescription | INTRAVENOUS |
| 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML ;147MG/100ML;3.9GM/100ML (1026ML) | EMULSION | Prescription | INTRAVENOUS |
| 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML) | EMULSION | Prescription | INTRAVENOUS |
| 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML) | EMULSION | Prescription | INTRAVENOUS |